US Foreign Aid

Business

Northland Cuts Bitdeer Price Target to $25 After December Update, Maintains Bullish Stance

Northland Capital has revised its price target for Bitdeer Technologies (BTDR) downward to $25, citing a more conservative valuation approach following the company's latest operational update. The firm, however, reaffirmed its Outperform rating, signaling continued confidence in the blockchain and high-performance computing firm's long-term strategy.

Jan 30, 2026

Business

Guggenheim Backs AtaiBeckley with Buy Rating, $11 Target, Citing Breakthrough Potential in Mental Health

Guggenheim Securities has initiated coverage of clinical-stage biopharma AtaiBeckley with a Buy rating and an $11 price target, highlighting its leadership in next-generation psychiatric treatments following its merger with Beckley Psytech.

Jan 30, 2026

Business

Geron Sees Price Target Cut to $3 by TD Cowen Ahead of Q4, But Buy Rating Stays

Analyst Tara Bancroft of TD Cowen lowered the firm's price target on Geron Corporation (GERN) from $4 to $3, maintaining a Buy rating ahead of the biotech's fourth-quarter results. The move reflects a model update as the company navigates mixed commercial progress for its blood cancer drug RYTELO.

Jan 30, 2026

Business

Citi Boosts Lexicon Pharmaceuticals Outlook on Novo Nordisk Partnership Progress

Citi raises Lexicon Pharmaceuticals' price target to $2.10, citing strong momentum from its collaboration with Novo Nordisk on obesity drug candidate LX9851 and improved financials.

Jan 30, 2026

Business

Sweetgreen Shares Slump Amid Growth Stock Sell-Off, Goldman Sachs Maintains Sell Rating

The fast-casual salad chain's stock fell sharply this week, pressured by a broader retreat in growth stocks and a reiterated sell call from Goldman Sachs, despite positive signals from the broader restaurant sector.

Jan 30, 2026

Business

Reed Jobs Launches $200M+ Venture Fund Aiming to Turn Cancer into a Manageable Condition

Reed Jobs, son of the late Apple co-founder Steve Jobs, has secured over $200 million for Yosemite, a venture fund dedicated to pioneering cancer treatments. Backed by major institutions, the fund seeks to transform cancer from a fatal diagnosis to a chronic, manageable disease within a generation.

Jan 30, 2026

Business

Arizona Price Report Sparks Debate: Economist Says Democratic Analysis Lacks Inflation Context

A recent report by Congressional Democrats highlights rising costs for Arizonans, but a local economist argues the figures lack crucial context on 'normal' inflation, igniting a political firestorm over economic messaging.

Jan 30, 2026

Business

Standex Posts Record Margins, Outlines Expansion Plans Amid Tariff Headwinds

Standex International reports consecutive quarters of record profitability, driven by strategic acquisitions and growth in electrical grid and aerospace markets, while navigating global trade uncertainties.

Jan 30, 2026

Business

Amazon Announces 16,000 Job Cuts: A Strategic Pivot or Sign of Strain?

Amazon is set to eliminate 16,000 corporate roles, marking its largest workforce reduction since 2023. As the tech giant streamlines operations and doubles down on AI, investors are weighing the long-term strategy against near-term turbulence.

Jan 30, 2026

Business

OpenAI's Reported 2026 IPO: A High-Stakes Test for the AI Investment Frenzy

Sources indicate OpenAI is accelerating plans for a late-2026 public listing, a move that would place its massive cash burn and long road to profitability under intense investor scrutiny, potentially defining the next phase of the AI boom.

Jan 30, 2026

Business

Analysts Sound Caution on ICF International as Backlog Shrinks, Point to Alternative Tech Play

While ICF International's stock has kept pace with the broader market, analysts highlight concerns over declining backlog and slowing revenue growth, suggesting investors may find better opportunities elsewhere.

Jan 30, 2026

Business

Therapeutics Sector Shows Resilience in Q3: United Therapeutics Lags as Halozyme and Biogen Outperform

A mixed third-quarter earnings season for therapeutics stocks reveals divergent paths, with United Therapeutics missing estimates while peers like Halozyme and Biogen post strong beats. Sector-wide revenue growth and positive stock reactions suggest underlying investor confidence despite regulatory and pricing headwinds.

Jan 30, 2026

Business

U.S. Drilling Activity Stalls Amid Mixed Signals for Oil and Gas

The U.S. rig count saw a marginal increase this week, yet remains significantly below last year's levels as crude production dips and completions activity sends conflicting signals.

Jan 30, 2026

Business

Oshkosh Navigates Tariff Headwinds and Mixed Demand to Set 2026 Course

Oshkosh Corporation topped revenue expectations in its latest quarter, but profit fell short as tariffs and cost pressures squeezed margins. The specialty vehicle maker's 2026 outlook balances targeted growth in some segments against persistent challenges in construction markets.

Jan 30, 2026

Business

Thermo Fisher Beats Q4 Estimates on Product Launches, Acquisitions; Shares Dip Amid Broader Concerns

Thermo Fisher Scientific posted stronger-than-expected Q4 revenue and profit, driven by new products and strategic deals. However, the stock fell as investors weighed pressures in key academic and government markets against the company's solid 2026 outlook.

Jan 30, 2026

Business

Three Mid-Cap Stocks Facing Headwinds: Why Analysts Are Sounding the Alarm

While mid-cap companies often represent a sweet spot between growth and stability, heightened competition and shifting market dynamics are putting pressure on some notable names. Here’s a closer look at three stocks where caution may be warranted.

Jan 30, 2026

Business

Navigating the Giants: One Large-Cap Stock with Room to Run, and Two Facing Headwinds

While large-cap stocks offer stability, their massive scale often limits growth. We analyze three market leaders, identifying one with compelling potential and two where the current story may be fully priced in.

Jan 30, 2026

Business

Beyond the Bottom Line: One Profitable Stock to Watch, Two to Approach with Caution

Profitability is a crucial starting point for investors, but it's not a guaranteed shield against market shifts. As competition evolves, today's cash generators can become tomorrow's laggards. We analyze three companies with strong margins to separate resilient growth from potential stagnation.

Jan 30, 2026

Business

Value Traps: Three 'Bargain' Stocks That May Not Be Worth the Risk

While the allure of finding the next undervalued gem is strong, some stocks trading at low multiples may be cheap for a reason. We examine three companies where fundamental challenges could outweigh their seemingly attractive valuations.

Jan 30, 2026

Business

Sales & Marketing Software Sector's Q3: Strong Results Meet Skeptical Market

While the sales and marketing software segment broadly exceeded revenue expectations in Q3, investor sentiment has turned sour, with most stocks falling post-earnings. We analyze the divergent performances of Upland Software, Sprinklr, DoubleVerify, PubMatic, and Sprout Social.

Jan 30, 2026